Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated and just as effective as the current standard 14 day regimen, according to a study published this week in The Lancet. These findings have important implications for the treatment and elimination of vivax malaria in the Asia Pacific.

Dr Bob Taylor, right, in a lab with colleagues at a South Sumatra, Indonesia IMPROV study site © 2019 MORU. Photographer: Prayoon Yuentrakul
Dr Bob Taylor, right, in a lab with colleagues at a South Sumatra, Indonesia IMPROV study site

Coordinated by the Menzies School of Health Research (Menzies, Darwin, Australia), the Mahidol Oxford Tropical Medicine Research Unit (MORU, Bangkok, Thailand) and the Eijkman Institute of Molecular Biology (Jakarta, Indonesia), the IMPROV (Improving the Radical Cure of Vivax Malaria) trial involved > 2,000 patients in Ethiopia, Afghanistan, Indonesia and Vietnam and tested the treatment effectiveness of a high-dose 7 day course of primaquine.

Its findings challenge the standard treatment regimen that has been widely used for the last 60 years.

The WHO recommends that patients with P. vivax malaria are treated with antimalarial drugs to clear the parasites in the blood followed by a 14-day course of primaquine to kill the liver hypnozoites and prevent recurrent bouts of malaria.

Associate Senior Clinical Research Fellow Dr Bob Taylor, MORU, says adherence to the standard 14-day regimen is poor.

“Primaquine is the only widely available drug that kills the P. vivax hypnozoites in the liver, but patients often fail to complete the treatment once they feel better. We found that the 7-day high-dose course of primaquine was as effective as the recommended 14-day treatment,” Dr Taylor said.

P. vivax malaria is a major cause of illness in Asia, Oceania, the Horn of Africa, and the Americas. The P. vivax parasites has dormant forms in the liver called hypnozoites, that wake up weeks to months later causing relapses - multiple episodes of malaria that lead to repeated illness and time out of work and school.

Senior Researcher Dr Kamala Thriemer (Menzies) says a shorter treatment prevents multiple episodes of malaria that lead to ill health particularly in young children and pregnant women.

“The shorter, 7 day primaquine regimen worked very well, with very few people having another episode of malaria within 12 months. Although some patients had minor side effects, the drug was generally well tolerated,” Dr Thriemer said.

The study’s principal investigator Prof Ric Price (University of Oxford) said: “Vivax malaria is becoming the predominant cause of malaria in the Asia Pacific. A short course primaquine regimen is much easier to administer and patients are more likely to complete treatment.

“If used widely, this new regimen could help reduce and accelerate the elimination of vivax malaria from the region,” said Prof Price.

Reference

Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Taylor et al, The Lancet.

Funders

This research was funded by the: UK Department for International Development, UK Medical Research Council, UK National Institute for Health Research, and the Wellcome Trust through the Joint Global Health Trials Scheme (MR/K007424/1) and the Bill & Melinda Gates Foundation (OPP1054404).

Similar stories

Risks of serious adverse events following treatment for visceral leishmaniasis

OCGHR Publication Research

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.